The pathology of schizophrenia is characterized by increased hippocampal activity at baseline and during auditory hallucinations. Animal-model studies in which the flow of activity to the hippocampus is increased through decreased amygdalar GABAergic inhibition have shown alterations of hippocampal circuitry similar to schizophrenia, but the functional importance of this phenomenon remains unclear. We provide evidence of decreased hippocampal feed-forward and tonic GABA-mediated inhibition in this animal model, complementing increased hippocampal activity seen in neuroimaging and postmortem studies. We demonstrate that GABA dysfunction increases long-term potentiation through activation of the cholinergic system, offering a new mechanism for pharmacological strategies of this disorder.
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amygdala ͉ hippocampus ͉ long-term potentiation ͉ GABA ͉ picrotoxin M any lines of evidence indicate that memory processing in the hippocampus is modulated by the amygdala (1) . Projections from the amygdaloid complex reach several hippocampal regions, providing various routes by which the amygdaloid complex may potentially influence hippocampal function (2, 3) . Reports suggest that inputs from the amygdala to the hippocampus via two separate pathways, the indirect perforant path and the direct pathway to CA2͞CA3, are responsible for alteration of the circuitry in CA4, CA3, and CA2 and, to a lesser extent, CA1 (4, 5) . Electrical stimulation of the basolateral amygdala (BLA) in anesthetized rats generates synaptic potentials in the dentate gyrus of the hippocampus, indicating that they are connected through neuronal projections (6) . In addition, emotional experiences are shown to activate the BLA, which, in turn, either enhances or impairs hippocampal longterm potentiation (LTP) (7) (8) (9) . Direct evidence demonstrating that neuronal inputs from the amygdala modulate hippocampal synaptic plasticity has come from lesions in the BLA that result in the decrease of LTP in the rat hippocampus (6) .
In the past 10 years, several studies have suggested that the relationship between the BLA and hippocampus may also contribute to the pathophysiology of schizophrenia (SZ) (10) (11) (12) . For example, brain-imaging studies have demonstrated volume reductions in both regions of schizophrenics (13) . Moreover, several postmortem studies have pointed to a deficit of GABAergic activity in SZ in cortical (14) (15) (16) (17) and subcortical areas, particularly hippocampal sectors CA3 and CA2, which receive abundant projections from the BLA (18, 19) . There is also a report showing direct evidence of a decrease of high-affinity GABA uptake in the amygdala of the postmortem schizophrenic brain (20) . It has been postulated that these changes might induce an increased outflow of excitatory activity from the amygdala to the hippocampus and induce alterations of hippocampal circuitry, particularly in GABAergic interneurons (18) . Such changes could influence LTP (21, 22) , perhaps contributing to emotional learning during adolescence, the period when the SZ phenotype is first manifest. To test this hypothesis, we have developed a ''partial'' rodent model, in which a low, nonepileptogenic dose of picrotoxin (PICRO), a noncompetitive antagonist of the GABA A receptor, is infused into the BLA to decrease GABAergic activity and increase the flow of excitatory activity to the hippocampus (5, 23) . With this partial model, it has been possible to generate changes in GABA cells similar to those reported in postmortem microscopic analyses of the hippocampus in SZ (23) .
Using gene expression profiling, we have demonstrated that acute administration of PICRO in the BLA results in an upregulation of the M1, M2, and M3 cholinergic receptor subtypes (24) . The septohippocampal cholinergic fiber system ramifies extensively throughout hippocampus formation and probably releases acetylcholine on these and other muscarinic receptor subtypes (25) (26) (27) (28) . This cholinergic system is believed to exert a strong influence on synaptic transmission and cellular excitability within hippocampal circuitry (29) (30) (31) and may even modulate information-processing via GABA inhibitory networks (32) (33) (34) , such as the ones that are postulated to be dysfunctional in SZ (35, 36) . The M1 subtype is the most abundant muscarinic receptor on pyramidal neurons in the hippocampus (37) (38) (39) and may represent an important target for developing new strategies to treat this disorder. Studies on which M1 muscarinic-receptorknockout mice have been used have demonstrated a fundamental role of this receptor in cognition and, by inference, in SZ (40) .
Based on our previous postmortem and partial rodent studies, we have predicted that there will be a decrease of hippocampal GABA current and changes in synaptic plasticity associated with the cholinergic system in rats receiving an infusion of PICRO in the BLA. The studies described below have tested this hypothesis by using agonists of the M1 and M3 receptors in a hippocampalslice preparation and have demonstrated increased amplitude of LTP and decreased amplitude of GABA currents, particularly in sector CA3 of PICRO-treated rats.
Materials and Methods
Stereotaxic Procedures. All the experiments were carried out by using Sprague-Dawley male rats (300 g), anesthetized (ketamine, 100 mg͞kg of body weight and xylazine, 40 mg͞kg of body weight; n ϭ 40) and placed in a stereotaxic device (Stoelting). A burr hole was drilled into the skull, and a Hamilton syringe (1.0 l) was used to infuse a low nonepileptogenic dose of PICRO (50 ng͞0. were obtained from pyramidal cells in the pyramidal layers of CA3 and CA1 in hippocampal slices, in PICRO-and SAL-treated rats, under visual guidance (differential interference contrast microscopy͞infrared optics) with an EPC-9 amplifier and PULSE V8.40 software (HEKA Electronics, Lambrecht͞Pfalz, Germany). The patch electrodes (3-to 5-M⍀ resistance) contained 120 mM KCl, 5 mM NaCl, 1 mM MgCl 2 , 0.2 mM EGTA, 10 mM Hepes, 2 mM MgATP, and 0.2 mM NaGTP (adjusted to pH 7.2 with KOH). The spontaneous GABAergic IPSCs were detected by using the program MINI ANALYSIS (Synaptosoft, Fort Lee, NJ). All values reported are means (ϮSEM) for n slices. Two-tailed Student's t test and two-way repeated-measures ANOVA were used for statistical comparison.
Results
To determine whether the cholinergic system may contribute to alterations of synaptic plasticity in the hippocampus, we stereotaxically infused PICRO or SAL into the rat BLA through a Hamilton syringe over a period of 45 min and killed the rats 96 h later. In this study, LTP was recorded after high-frequency stimulation in the stratum radiatum of sectors CA1 and CA3 in hippocampal slices. In particular, we investigated the possible modulatory role of agonists of the M1 (McN-A-343) and M1͞M3 (carbachol) receptors on LTP in the PICRO model (29, 41) . As an initial step, LTP (100-Hz tetanus for 1 s) of the fEPSP was induced in the absence of PICRO in the bath in CA1 or CA3 areas of PICRO-and SAL-treated rats. Blockade of GABA activity by PICRO injection in the BLA did not alter hippocampal LTP amplitude recorded 50 min after tetanus in sectors CA3 (152 Ϯ 9%, n ϭ 5 for SAL and 141 Ϯ 8%, n ϭ 5 for PICRO; P ϭ 0.075) or CA1 (138 Ϯ 5%, n ϭ 5 for SAL and 142 Ϯ 7%, n ϭ 5 for PICRO; P ϭ 0.32) (Fig. 1 a and b) . To test whether the M3 or M1 muscarinic receptors are involved in the regulation of synaptic plasticity in the PICRO-treated rats, we perfused hippocampal slices with the M1͞M3 receptor agonist carbachol, a nonselective mChR agonist that activates both M1 and M3 receptors equally well (42, 43) . Before delivery of high-frequency stimulation, bath application of carbachol (0.25 M) was associated with a brief depression of EPSP that promptly recovered, reaching a stable baseline for a period of at least 30 min. After tetanic stimulation, PICRO-treated rats showed an increased amplitude of LTP in sectors CA3 (158 Ϯ 4%, n ϭ 5 for SAL and 206 Ϯ 4%, n ϭ 5 for PICRO; P ϭ 0.0001) and CA1 (154 Ϯ 4%, n ϭ 5 for SAL and 191 Ϯ 5%, n ϭ 5 for PICRO; P ϭ 0.0001), when compared with SAL-treated rats (Fig. 2 a and b) .
Activation of M1 Receptors Recovers a Decrease of LTP in CA3 in the
Rodent Model of SZ. To distinguish M3 receptors from the subpopulation of M1 receptors involved in this model, hippocampal slices were infused with the M1 agonist McN-A-343 (10 m). LTP recorded from sector CA1 showed no significant effect of M1-receptor stimulation in either PICRO-or SALtreated rats (132 Ϯ 4%, n ϭ 5 for SAL and 137 Ϯ 6%, n ϭ 5 for PICRO; P ϭ 0.1596). In contrast, sector CA3 showed a marked decrease of LTP amplitude in control rats, but this inhibition was removed in the PICRO-treated animals (115 Ϯ 7%, n ϭ 5 for SAL and 144 Ϯ 9%, n ϭ 5 for PICRO; P ϭ 0.0005) (Fig. 2 c-e) . These latter results also show how LTP is differentially regulated by the muscarinic system in these two hippocampal areas by amygdalar activation.
Taken together, these data indicate that cholinergic input coming from M3 and M1 receptors facilitates synaptic plasticity in a model representing a GABA dysfunction in SZ.
Quantification of Hippocampal GABA Activity in the SZ Rodent Model.
Using whole-cell recording techniques, we next measured GABA A currents in rat hippocampal slices in the SZ model. With a stimulating electrode placed in the stratum radiatum to directly stimulate interneurons, IPSCs were recorded in pyramidal cells in CA3 and CA1 areas in hippocampal slices from both PICRO-and SAL-treated rats (Fig. 3a) . Pyramidal neurons were distinguished from interneurons, based on their morphological appearance and their ability to show spike-frequency adaptation to a prolonged depolarizing current injection. To isolate GABA currents, glutamatergic synaptic transmission was blocked by the NMDA receptor antagonist D-AP5 (50 M) and the ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor antagonist CNQX (20 M) at a holding potential of Ϫ70 mV (44) . The input͞output curves of the GABA IPSCs were obtained by recording 10-15 responses and averaging the recordings for each stimulation intensity tested. The intensity of stimulation was gradually increased from the threshold stimulus, determined in each individual experiment, to produce IPSCs of increasing amplitude. ANOVA of the input͞ output curves revealed a significant decrease of GABA IPSCs that occurred in sectors CA1 (P ϭ 0.037) and CA3 (P ϭ 0.029) of PICRO-treated rats when compared with SAL-treated rats ( Fig. 3 b and c) . The observed decreases in the level of feed-forward GABAergic inhibition of principal neurons were more pronounced in sector CA3 than in CA1. We also tested whether infusion of PICRO in the BLA led to changes in the level of tonic inhibition in hippocampal neurons. Spontaneous IPSCs (sIPSCs) were recorded in hippocampal pyramidal neurons at a holding potential of Ϫ70 mV, in the presence of D-AP5 and CNQX to abolish the contribution of glutamatergic inputs. The sIPSCs recorded under these conditions were completely blocked by PICRO (50 M) in the bath, confirming that the sIPSCs are mediated by GABA A receptors.
No change in the frequency of events (sIPSCs) was observed in PICRO-treated rats, when compared with the SAL-treated group (CA1: 2.53 Ϯ 0.54 Hz for SAL; 2.31 Ϯ 0.51 for PICRO; n ϭ 6 cells; t ϭ 0.39, P ϭ 0.71 and CA3 sector: 2.6 Ϯ 0.5 Hz for SAL; 2.49 Ϯ 0.5 for PICRO; n ϭ 6 cells; t ϭ 0.25, P ϭ 0.53). The mean amplitude of sIPSCs was significantly decreased in CA3 (SAL, 49.53 Ϯ 0.15 pA; PICRO, 24.84 Ϯ 0.23 pA; n ϭ 6, t ϭ 6.02, P ϭ 0.0009), as evidenced by a significant shift of amplitude toward smaller events, whereas CA1 did not show any changes (SAL, 50.52 Ϯ 0.28 pA; PICRO, 52.98 Ϯ 0.11 pA; n ϭ 6, t ϭ Ϫ0.6721, P ϭ 0.5265) (Fig. 4 a and b and data not shown for CA1 area).
Discussion
By using a partial rodent model, the studies reported here demonstrate that amygdalar activation of the hippocampus is associated with a decrease of GABA-mediated inhibition of principal neurons, particularly in sector CA3, where GABAergic dysfunction is believed to occur in SZ (19) . Behavioral observations after PICRO administration in the BLA demonstrated no evidence of seizure activity, whereas preliminary in vivo recordings, rather than showing ictal discharges, demonstrated a reduction of spontaneous activity in sectors CA3͞2 of PICROtreated rats. The latter observations argue compellingly against the idea that amygdalar activation, as used in this report, was associated with the induction of seizures.
The electrophysiological changes observed in the hippocampal-slice preparations obtained from SAL-and PICRO-treated rats could involve both pre-and postsynaptic elements, an idea that is in accordance with the recent demonstration that the BLA is capable of inducing changes in GABAergic axon terminals and second messengers and receptors (19) . The current finding confirms postmortem studies that suggest a deficit of GABAergic activity associated with a decrease in high-affinity GABAuptake sites in SZ subjects (45) and the expression of mRNA for the 65-kDa isoform of glutamate decarboxylase (46) , although the latter showed more pronounced reductions in bipolar subjects than in schizophrenics. The observed decrease in sIPSC amplitude in the present work complements previous human studies that show a compensatory up-regulation of the GABA-A receptor in the hippocampus of schizophrenics (47) and may, therefore, derive from a variety of pre-and͞or postsynaptic factors, such as the GABA content of synaptic vesicles that appears to be decreased in PICRO-treated rats. This decrease of GABA current in the rodent model of SZ represents electrophysiological evidence of a deficit in hippocampal GABA activity in this disorder and is also consistent with a recent positron-emission tomography (PET) imaging study showing increased levels of metabolic activity in the hippocampus of schizophrenic subjects at baseline conditions and during auditory hallucinations (48) . Overall, these proposed changes in the hippocampal GABA system might be expected to induce an increase of excitatory activity and, in this setting, might be expected to result in an excessive influx of Ca 2ϩ through the NMDA receptor channel. Changes of this type could influence intracellular signaling pathways associated with apoptosis (49) and ultimately affect synaptic equilibrium within hippocampal circuitry (50) (51) (52) .
M1 and M3 muscarinic receptors have been shown, at least in part, to decrease GABAergic tone, and it is notable that their expression is up-regulated in the partial model. In light of this fact, the unique efficacy of the atypical antipsychotic drug clozapine (53) may theoretically restore the activity of the GABA system to a normal level by blocking these, and probably other, monoaminergic receptors. Furthermore, M1͞M3 receptor activation may facilitate the firing of pyramidal neurons, a change that would lead to the observed increases in LTP magnitude. This increased firing of pyramidal cells might, in turn, induce oxidative stress in GABAergic cells, causing the observed reduction in IPSCs and sIPSCs reported here. Overall, the results of this study are consistent with the hypothesis that amygdalar activation of the hippocampus is associated with changes in gene regulation that result in a decrease of inhibitory control of pyramidal neurons (Fig. 4c) .
Consequently, understanding the influence of the BLA on the synaptic plasticity of GABAergic elements in the hippocampus may be beneficial in helping to develop pharmacological strategies for the treatment of SZ and other psychotic disorders (54) (55) (56) . 
